Prometheus raised $12 billion to build “artificial general engineers” aimed at accelerating biopharma workflows, according to a STAT+ report on the company’s capital push. The fundraising highlights continued investor appetite for AI agents that can perform or automate parts of drug development, including aspects of clinical trial operations. The same update also referenced broader AI use cases in biopharma beyond Prometheus, including partnerships that target clinical trial recruitment optimization. For industry participants, the scale of the Prometheus round signals that capital is consolidating around tooling expected to reduce development friction. The announcement arrives as companies seek ways to speed clinical timelines and improve trial execution, not just generate scientific hypotheses.